Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Change On The Horizon, Current Business Models In China Are Not Sustainable – So What’s Next?

This article was originally published in PharmAsia News

Executive Summary

Healthcare reforms will turn the China healthcare market upside now, meaning that pharma companies must prepare for a new sustainable business model.

Advertisement

Related Content

Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
With Latest Round Of Cuts, China Continues March To Narrow Gap Between Big Pharma And Local Generics
Expansion Into China's Lower-tier Cities Could Be Growth Driver For Big Pharma
Lilly Shifts Gears In China With New Shanghai-based R&D Center

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC080677

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel